Announcements Trials

Browse Landscape

Phase

Phase 1 21 Phase 2 6 Phase 1/2 4 Phase NA 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Leiomyosarcoma 1

Interventions

Cisplatin 726 Carboplatin 609 Paclitaxel 579 Cyclophosphamide 516 Radiotherapy 511 Docetaxel 477 Fluorouracil 454 Gemcitabine 438 Doxorubicin 383 Capecitabine 362 Dexamethasone 328 Oxaliplatin 289 pembrolizumab 283 Leucovorin 283 Bevacizumab 275 Etoposide 272 Vincristine 270 Rituximab 246 Prednisone 223 Pemetrexed 217 Cytarabine 205 Drug Therapy 194 Trastuzumab 176 Irinotecan 174 Methotrexate 171 Lenalidomide 137 Nivolumab 136 Filgrastim 135 Epirubicin 129 Tamoxifen 128

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Digoxin × Clear all

NCT03016819 2026-02-25

APROMISS

Advenchen Laboratories, LLC

Phase 3 Recruiting

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon ⚡